Valneva Austria Gmbh

This study was designed to test a vaccine called VLA1553 to prevent chikungunya virus infection in healthy children aged 1 to 11 years. The trial planned to enroll over 3,000 children and compare the vaccine to a standard shot. However, the study was withdrawn before any particip…

This study follows 5,000 people who received the VLA1553 chikungunya vaccine to check for side effects like arthritis, heart problems, or chikungunya-like symptoms. Researchers will track these issues for up to 60 days after vaccination. The goal is to make sure the vaccine is sa…

This study looks at how effective the VLA1553 vaccine is at preventing chikungunya virus disease in a real-world setting in Brazil. Researchers will compare vaccinated and unvaccinated people who have chikungunya-like symptoms to see if the vaccine reduces infections. About 1,200…

This study looks at how long the chikungunya vaccine (VLA1553) keeps working and if it stays safe over time. About 363 adults who got the vaccine in an earlier trial are being followed. Researchers measure antibody levels and watch for any serious side effects.

This study is testing over 5,300 people in about 10 Brazilian towns to see how many have already been exposed to the chikungunya virus before a new vaccine (VLA1553) is offered. Participants are aged 2 and older and live in selected households. The goal is to understand how past …